Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Incidence of breast cancer in patients with multiple sclerosis treated with disease modifying therapies (ocrelizumab, interferon beta-1a, interferon beta-1b, glatiramer acetate, dimethyl fumarate, fingolimod, teriflunomide, alemtuzumab, natalizumab, and rituximab)

Next Previous
Search
Trial Profile

Incidence of breast cancer in patients with multiple sclerosis treated with disease modifying therapies (ocrelizumab, interferon beta-1a, interferon beta-1b, glatiramer acetate, dimethyl fumarate, fingolimod, teriflunomide, alemtuzumab, natalizumab, and rituximab)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Glatiramer acetate (Primary) ; Interferon beta-1a (Primary) ; Interferon beta-1b (Primary) ; Natalizumab (Primary) ; Ocrelizumab (Primary) ; Rituximab (Primary) ; Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions

    • Most Recent Events

    • 11 Apr 2022 New trial record
    • 26 Feb 2022 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top